Contineum shares fell 9.9% due to the failure of mid-term clinical trials of an antidepressant developed in collaboration with Johnson & Johnson.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.